Literature DB >> 7131485

Carboxyimamidate, a low-molecular-weight polyelectrolyte with antitumor properties and low toxicity.

J E Fields, S S Asculai, J H Johnson, R K Johnson.   

Abstract

A new polyelectrolyte was synthesized and evaluated for antitumor activity. The product is a derivative of ethylene/maleic anhydride copolymer of low molecular weight (Mn approximately equal to 1100). The anhydride groups were first converted to the half-amide, half-ammonium salt by reaction with ammonia. A percentage (14-25 wt %) of these groups was further converted to the imide by heating. The product, carboxyimamidate (Carbethimer, N-137) inhibited the growth of a number of solid tumors in vivo. Sensitive tumor models included Lewis lung carcinoma, Madison 109 lung carcinoma, M5076 ovarian tumor, colon carcinoma 26, B16 melanoma, and P815 mastocytoma. Activity was dose related between nontoxic dose levels of 300 and 2000 mg/kg ip.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7131485     DOI: 10.1021/jm00351a011

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Phase II study of carbetimer in non-small cell lung cancer.

Authors:  M Keaton; T Brown; J Craig; G Fries; G Harmon; A Zaloznik; G Orczyk; D Von Hoff
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

2.  Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks.

Authors:  M Fromm; W E Berdel; H D Schick; S Danhauser-Riedl; U Fink; W Remy; A Reichert; A Ankele; H W Präuer; J R Siewert
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

3.  Phase I trial of a 5-day course of carbetimer.

Authors:  S M Grunberg; E Ehler; R B Francis; M S Mitchell
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

4.  Activity of Carbetimer in a human tumor cloning system.

Authors:  D L Kisner; P Mehta; G E Paget; D D Von Hoff
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

5.  Phase II trial of carbetimer in metastatic melanoma.

Authors:  W D Quan; M S Mitchell
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.